Over the past year, many tech heavyweights have begun moving into the mHealth sector. Developers got an early look at Google's offering this week, with the search giant releasing a preview version of its APIs for health app developers.
Every year the FDA receives hundreds of Freedom of Information Act requests from biopharma companies for adverse-event data, while others take equally laborious steps to access the information. Now the FDA is opening up its adverse-event data through an application programming interface.
The Merck executive leading the company's digital innovation unit has warned that Boston's startups can still improve, particularly with regards to the degree of scientific rigor applied to their apps.
Beth Noveck's mission has been to apply the transparency and collaboration of the open-source movement to government. Noveck has now left the White House, but the ideas she brought are still percolating through the governmental machine. In 2014, the thinking is set to lead to a new, more open FDA.
The FDA has moved tentatively into the world of smartphones and social media, with its guidance often lagging behind industry expectations and its own activities being grown carefully. These in-house initiatives are now due to gain a new component. The FDA is working on a drug shortages smartphone app.
Smartphones and tablets succeed or sink on the strength of their apps. Over the past few years, this has given Apple ($AAPL) a huge advantage. If you wanted the latest apps, Apple was the only...
HopeLab has released a new mobile game for children with cancer to play during chemotherapy, seeking to improve adherence to meds and spark positive thoughts during treatment.
Genentech, the venerable biotech unit of Roche, has been cranking out new mobile apps to stay ahead in the biopharma world.
Cancer patients might fail to follow their doctor's orders often. But how often do they forget their mobile phones?
Fresh data have emerged in the ongoing debate over the regulation of medical apps for smartphones and mobile devices. Researchers questioned the accuracy of four apps for evaluating skin lesions in a study, generating some troubling results and pointing out that such apps have gone unregulated.